Estradiol pill for ER-positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether an estradiol (a form of estrogen) treatment can help people with ER-positive advanced breast cancer. It is mainly for post-menopausal women whose cancer is not curable and has already been treated with endocrine (hormone) therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are post-menopausal (have gone through menopause).
- Your breast cancer is ER-positive (uses estrogen to grow).
- Your cancer is advanced—either metastatic or a recurrence that cannot be cured with surgery or radiation alone.
- You have already had at least one hormone-based treatment for advanced disease.
- While taking the study estradiol, you generally cannot take other cancer medicines at the same time (except certain allowed options).
- You do not have certain serious heart/blood-clot/stroke history, and any brain disease must be stable for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether combining estradiol (a form of estrogen) with olaparib (a targeted cancer medicine) can control ER-positive, HER2-negative breast cancer that has spread or come back. It may help by attacking cancer cells in a new way after standard hormone-based treatments.
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This study tests a new approach using a special diet combined with a medication to see if it can improve the effectiveness of hormone therapy for women with ER-positive, HER2-negative metastatic breast cancer. The trial will help determine if this diet can slow cancer growth and potentially delay the need for chemotherapy.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.